Table 1.
Ref. | Trial acronym | Yr | BD-DES type | PP-DES type | Total patients | BD-DES patients | PP-DES patients |
Natsuaki et al[8] | NEXT | 2013 | Biolimus | Everolimus | 3235 | 1617 | 1618 |
Smits et al[9] | COMPARE 2 | 2013 | Biolimus | Everolimus | 2707 | 1795 | 912 |
Gao et al[10] | TARGET 1 | 2013 | Sirolmus | Everolimus | 458 | 227 | 231 |
Byrne et al[11] | ISAR-TEST 4 | 2011 | Sirolimus | Everolimus | 2603 | 652 | 1304 |
Xu et al[12] | 2011 | Sirolimus | Zotarolimus | 324 | 168 | 156 | |
Separham et al[13] | 2011 | Biolimus | Everolimus | 200 | 100 | 100 | |
Meredith et al[14] | EVOLVE | 2012 | Biolimus | Everolimus | 192 | 98 | 94 |
Pilgrim et al[15] | BIOSCIENCE | 2014 | Sirolimus | Everolimus | 2119 | 1063 | 1056 |
Serruys et al[7] | ABSORB 2 | 2014 | Everolimus | Everolimus | 501 | 335 | 166 |
Lee et al[16] | 2014 | Biolimus | Everolimus | 500 | 245 | 255 | |
Windecker et al[17] | BIOFLOW 2 | 2014 | Sirolimus | Everolimus | 452 | 298 | 154 |
BMS: Bare metal stents; PP-DES: Permanent polymer drug eluting stents; BD-DES: Biodegradable polymer drug eluting stents.